> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review Voucher for Adzynma Approval
- URL: https://www.fdaweb.com/priority-review-voucher-for-adzynma-approval/
- Published: 2024-01-10T12:00:00.000Z
- Updated: 2026-09-14T14:20:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156115

*Federal Register* notice: FDA is announcing the issuance of a priority review voucher to Takeda Pharmaceuticals for its qualified rare pediatric disease product application — Adzynma (ADAMTS13, recombinant-krhn), indicated for prophylactic or on-demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-00401.pdf?ref=fdaweb.com).